Cancer-fighting drugs being developed by Sanofi and other companies
Sanofi is joining hands with Evotect (from Germany) and Apeiron Biologics (Austria) to introduce to the market immune oncology pills (pills that fight tumors and blood cancers).
Under the collaboration, Sanofi has the option of screening its own compound libraries to identify new small-molecule candidates for development, it said in a statement.
The group will support two years of research funding for Evotec and Apeiron and pay Evotec potentially more than 200 million euros ($219 million) if promising molecules are identified.
The French group said it would have sole responsibility for all development, regulatory, commercial and manufacturing activities of the products.
Last week, Sanofi announced a partnership with Evotec to develop stem cell-based treatments for diabetes.
The company is also working closely with its long-time partner Regeneron Pharmaceuticals in the area of cancer immunotherapy.
Category: Features, Pharmaceuticals
